Compare AEVA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | MDXG |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | 239 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 530.2M |
| IPO Year | N/A | 2007 |
| Metric | AEVA | MDXG |
|---|---|---|
| Price | $20.88 | $3.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $26.50 | $9.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.7M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $85.37 | N/A |
| Revenue Next Year | $132.72 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $8.83 | $3.03 |
| 52 Week High | $38.79 | $7.99 |
| Indicator | AEVA | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 64.00 | 56.02 |
| Support Level | $12.37 | $3.45 |
| Resistance Level | $21.64 | $7.39 |
| Average True Range (ATR) | 2.32 | 0.13 |
| MACD | 0.40 | 0.05 |
| Stochastic Oscillator | 86.60 | 93.83 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.